ALCLS Cellectis SA

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

PARIS, 03 nov. 2023 (GLOBE NEWSWIRE) --

Place de cotation : Euronext Growth

Code ISIN : FR0010425595

Date		Nombre total d’actions composant le capital socialNombre total de droits de vote
31/10/202355 583 76861 519 396

Pour de plus amples informations sur Cellectis, veuillez contacter :        

Contact média :        

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,

Contacts pour les relations avec les investisseurs :        

Arthur Stril, Chief Business Officer, +1 (347) 809 5980,          

Sandya von der Weid, Associate Director, LifeSci Advisors, 8      

Pièce jointe



EN
03/11/2023

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Baptiste Salaville ... (+2)
  • Baptiste Salaville
  • Margaux van Oerle
INFINEON INFINEON TECHNOLOGIES AG
LOGN LOGITECH INTERNATIONAL S.A.
RBT ROBERTET SA
ALCLS CELLECTIS SA
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
COTN COMET HOLDING AG
CICN CICOREL HOLDING S.A.
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
WAF SILTRONIC AG
MELE MELEXIS NV
NOD NORDIC SEMICONDUCTOR ASA
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
JEN JENOPTIK AG
SPAC 468 SPAC I SE
ARM ARM HOLDINGS PLC
AMS AMS-OSRAM AG
IFCN INFICON HOLDING AG
04/14/26 April 14, 2026 1 FR
Baptiste Salaville ... (+2)
  • Baptiste Salaville
  • Margaux van Oerle
INFINEON INFINEON TECHNOLOGIES AG
LOGN LOGITECH INTERNATIONAL S.A.
RBT ROBERTET SA
ALCLS CELLECTIS SA
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
COTN COMET HOLDING AG
CICN CICOREL HOLDING S.A.
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
WAF SILTRONIC AG
MELE MELEXIS NV
NOD NORDIC SEMICONDUCTOR ASA
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
JEN JENOPTIK AG
SPAC 468 SPAC I SE
ARM ARM HOLDINGS PLC
AMS AMS-OSRAM AG
IFCN INFICON HOLDING AG
04/14/26 April 14, 2026 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
04/14/26 April 14, 2026 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
04/14/26 April 14, 2026 1 FR
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ A...

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today highlights the interim futility analysis announced by Allogene Therapeutics, Inc. (“Allogene”) from Allogene’s sponsored pivotal ALPHA3 trial evaluating cema-cel in first-line consolidation for large B-cell lymphoma (LBCL). Cema-cel is a product can...

April 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch